Biology of the Oral Epithelium of E-Cigarette Smokers

NCT ID: NCT03028558

Last Updated: 2021-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

105 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-12

Study Completion Date

2021-01-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Electronic cigarettes (EC) are battery powered nicotine delivery devices that aerosolize nicotine and other flavor constituents. Despite the increasing use of EC, little attention has been paid to their possible adverse effects on human health. Theoretically, the risk relates to nicotine per se and/or the propellants or contaminants in the EC aerosol. The hypothesis underlying the proposal is that chronic EC smoking disorders the biology of the oral epithelium, the first cell population exposed to inhaled EC vapors. Using a cross-sectional, cohort-comparison of EC smokers compared to age-, gender- and ethnicity-matched never smokers, the investigators propose to assess the oral epithelium obtained by punch biopsy or brushing from 100 EC smokers and 25 nonsmoker controls. The EC study cohort will be restricted to young adults (age 21-35 yr) with no prior history of tobacco smoking, but who have smoked EC for \>6 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is compelling evidence to support this hypothesis: (1) EC vapors contain nicotine, the oral epithelium expresses nicotine receptors, and exposure of epithelia to nicotine activates the nicotine pathway; (2) EC vapors also contain chemical contaminants that can potentially effect oral epithelial biology; and (3) in vitro studies suggest that EC vapors modify epithelial biology and data generated by our laboratory demonstrates that even a brief, acute exposure of healthy nonsmokers to EC vapors induces significant changes in the airway epithelial transcriptome, including the expression of genes in the nicotine and p53 pathways. With the knowledge that disordering of cell biology occurs long before clinical disease,the investigators will evaluate the oral epithelium at the transcriptome (mRNA and miRNA) levels. They will then identify gene(s)/pathways/communities disordered by EC vapors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HEALTHY VOLUNTEER RESEARCH SUBJECTS

Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.

Between the ages of 21-35 years old.

No interventions assigned to this group

HEALTHY E-CIGARETTE SMOKING SUBJECTS

Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes \>5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HEALTHY VOLUNTEER RESEARCH SUBJECTS:


* Males and females, ages 21 to 35
* Must be capable of providing informed consent
* Self-reported never-smokers of any type, including chewing tobacco, with current smoking status validated by the absence of nicotine metabolites in urine (nicotine \<2 ng/ml and cotinine \<5 ng/ml)
* No bleeding diathesis
* Normal physical examination
* Good overall health without history of oral or lung disease
* Normal routine laboratory evaluation, including general hematologic studies, general serologic/immunologic studies, general biochemical analyses, and urine analysis
* Not taking any medications relevant to lung disease or having an effect on the airway epithelium
* Normal chest X-ray (PA and lateral)
* Normal electrocardiogram (sinus bradycardia, premature atrial contractions are permissible)
* Females - not pregnant
* Willingness to participate in the study

* HEALTHY VOLUNTEER E-CIGARETTE SMOKING SUBJECTS:


* Males and females, ages 21 to 35
* Must be capable of providing informed consent
* E-cigarette smokers with current smoking status validated by nicotine metabolites in urine (nicotine \>20 ng/ml and cotinine \>30 ng/ml)
* No bleeding diathesis
* Normal routine laboratory evaluation, including general hematologic studies, general serologic/immunologic studies, general biochemical analyses, and urine analysis
* Good overall health without history of oral disease
* Normal spirometry
* All individuals have chest X-ray (PA and lateral)
* Normal electrocardiogram (sinus bradycardia, premature atrial contractions are permissible)
* Females - not pregnant
* Willingness to participate in the study

* Have smoked any form of tobacco
* Current marijuana smokers (within the last three months)
* Current active infection or acute illness of any kind
* Evidence of malignancy, including oral cancer
* Current pregnancy

* HEALTHY VOLUNTEER E-CIGARETTE SMOKING SUBJECTS:

* Have smoked any form of tobacco
* Current marijuana smokers (within the last three months)
* Current active infection or acute illness of any kind
* Evidence of malignancy, including oral cancer
* Current Pregnancy

Exclusion Criteria

* HEALTHY VOLUNTEER RESEARCH SUBJECTS:
Minimum Eligible Age

21 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Weill Medical College of Cornell University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald G Crystal, MD

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Genetic Medicine, Weill Cornell Medical College

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1512016796

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Burning Mouth Syndrome: Symptoms and Management
NCT07016555 RECRUITING EARLY_PHASE1
Local Pilocarpine for Relieving Dry Mouth
NCT04195100 COMPLETED EARLY_PHASE1